Frontlight ResearchEarly access
CompletedPhase 1
To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects
Key facts
- Who runs it
- Jiaxing AnDiCon Biotech Co.,Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 16 people enrolled
- Started
- 14 Mar 2024
- Ended
- 21 Jun 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- ADC189
- Record updated
- 20 January 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- 1) The subjects fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign a written informed consent, and can complete the entire trial process according to the requirements of the trial
- 2) Age 18-75 years old (including the boundary value), both male and female
- 3) The body weight of male subjects was ≥50 kg, the body weight of female subjects was ≥45 kg, and the body mass index (BMI) was within the range of 18.0~30.0 kg/m²
Who cannot take part
- 3) Patients with severe infection, trauma, gastrointestinal surgery or other major surgical operations within 4 weeks before screening
- 1) Known allergic history to test drug components, or allergic constitution, or history of allergic diseases
- 2) Have malignant tumors, or have a history of malignant tumors within 5 years prior to screening
- 4) eGFR (CKD-EPI Cr) <60mL/min/1.73m2
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of ADC189 in subjects with hepatic impairment compared with subjects with normal hepatic function.
The 4 groups in the trial
- ADC189 to Child-Pugh Class ATreatment being tested
Subjects with Child-Pugh Class A received a single dose once of ADC189 (45 mg/1 tablet).
Treatment: ADC189
- ADC189 to normal haptic function (A)Treatment being tested
Healthy subjects who marched with Group "Child-Pugh Class A", that received a single dose of ADC189 (45 mg/1 tablet).
Treatment: ADC189
- ADC189 to Child-Pugh Class BTreatment being tested
Subjects with Child-Pugh Class B received a single dose once of ADC189 (45 mg/1 tablet).
Treatment: ADC189
- ADC189 to normal haptic function (B)Treatment being tested
Healthy subjects who marched with Group "Child-Pugh Class B", that received a single dose of ADC189 (45 mg/1 tablet).
Treatment: ADC189
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Phase I, Open-label, Multi-center, Parallel, Single Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ADC189 in Subjects With Hepatic Impairment (Child-Pugh A and B) Compared With Subjects With Normal Hepatic Function
- Record updated
- 20 January 2025